Latest Reclast Stories
A new analysis of popular bone-building drugs by the US Food and Drug Administration (FDA) could prompt millions of women to rethink their use of such drugs, even though the agency fell short of issuing specific recommendations.
EAST HANOVER, N.J., Oct.
- Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis(1) - Approximately 22 million women in US have osteopenia, or low bone mass, putting them at increased risk of fractures of hip, spine and wrist(2,3) - Reclast already approved as once-yearly infusion for treatment of postmenopausal osteoporosis(1) EAST HANOVER, N.J., June 1 /PRNewswire/ -- Reclast(R) (zoledronic acid) Injection has been approved...
- Having no light.